Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
Background: Nusinersen is an antisense-oligonucleotide (ASO) approved for treatment of 5q-spinal muscular atrophy (SMA). Since the drug cannot cross the blood-brain barrier (BBB), it must be administered into the cerebrospinal fluid (CSF) space repeatedly by lumbar puncture. However, little is known...
Main Authors: | Claudia D. Wurster, Jan C. Koch, Isabell Cordts, Jens Dreyhaupt, Markus Otto, Zeljko Uzelac, Simon Witzel, Benedikt Winter, Tugrul Kocak, Michael Schocke, Patrick Weydt, Kurt Wollinsky, Albert C. Ludolph, Marcus Deschauer, Paul Lingor, Hayrettin Tumani, Andreas Hermann, René Günther |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.01179/full |
Similar Items
-
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
by: Claudia D. Wurster, et al.
Published: (2019-05-01) -
Quality of Life in SMA Patients Under Treatment With Nusinersen
by: Lucas Mix, et al.
Published: (2021-03-01) -
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
by: Alma Osmanovic, et al.
Published: (2021-03-01) -
Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
by: René Günther, et al.
Published: (2019-11-01) -
Respiratory function in adult patients with spinal muscular atrophy treated with nusinersen – a monocenter observational study
by: Claudia Diana Wurster, et al.
Published: (2024-04-01)